OCMF 2022
Access the 2022 Conference recording on VuMedi
Download the 2022 Agenda
Distinguished Keynote Speakers
Joanna Burdette, PhD
Topic: PAX8 as a target in high grade serous ovarian cancer
University of Illinois, Cancer Center
David Bowtell, PhD
Topic: Women who beat the odds: Molecular analysis of long-term high grade serous ovarian cancer survivors
Peter MacCallum Cancer Centre, Melbourne VIC, Australia
2022 Speakers
Mesenchymal stem cells: architects of the ovarian cancer stromal microenvironment Lan Coffman, M.D., Ph.D. University of Pittsburgh School of Medicine Cellular networking via tunneling nanotubes in ovarian cancer Emil Lou, M.D., Ph.D. University of Minnesota School of Medicine Cyclic Immunofluorescence as a geospatial approach to ovarian cancer Sandro Santagata, M.D., Ph.D. Harvard Medical School Mechanobiology in ovarian cancer Sharon Stack, Ph.D. University of Notre Dame Tumor innervation in ovarian cancer Paola Vermeer, Ph.D. University of South Dakota Targeting quiescent cancer cells to overcome chemotherapy resistance Ron Buckanovich, M.D., Ph.D. Magee Women’s Research Institute & Foundation Modulating tumor immune response, tumor stemness, and treatment resistance by targeting microRNA-181a Analisa DiFeo, Ph.D. University of Michigan School of Medicine Unfolded protein response pathway and ovarian cancer stem cells Daniela Matei, M.D. Northwestern Feinberg School of Medicine Post-treatment enrichment of ovarian cancer stem cells Bo R. Rueda, Ph.D., M.S. Massachusetts General Hospital Harnessing the anti-angiogenic and anti-cancer stem cell properties of FKBPL; discovery to clinic in ovarian cancer Tracy Robson, Ph.D., RCSI Dublin, Co. Dublin, Ireland The Epigenome of Tubal Precursors and Ovarian Cancer Hui Shen, Ph.D. Van Andel Institute Heterogeneity of acquired resistance in ovarian cancer Liz Christie, Ph.D. Peter MacCallum Cancer Centre
Adaptive responses contributing to treatment resistance in ovarian cancer Jeremy Chien, Ph.D. University of California - Davis Modeling Ovarian Cancer in Post-menopausal setting Kathleen Cho, M.D., University of Michigan School of Medicine Rewiring of Transcriptional Circuits During Ovarian Cancer Development Kate Lawrenson, Ph.D. Cedars Sinai Research Center Why the fallopian tube? Shailja Pathania, Ph.D. University of Massachusetts Gamma Delta T Cells in Ovarian Cancer Michael Uhlin, Ph.D. Karolinska Institute, Sweden The Dietary Supplement Taurine Reactivates CDKN1A to Suppress Ovarian Cancer Growth Marcin Iwanicki, Ph.D. Stevens Institute of Technology Cell-derived Extracellular matrix remodeling a key orchestrator of ovarian chemoresistance Pilar de la Puente, Ph.D. Sanford Research Cancer-associated mesothelial cells promote the early stages of ovarian cancer metastasis Preety Bajwa, Ph.D. University of Chicago Single cell epigenomic profiling of high grade serous carcinoma Alexandre Gaspar-Maia, Ph.D. Mayo Clinic On the Road to Precision Medicine in Ovarian Cancer: One Cell at a Time Boris Winterhoff, M.D., M.S. University of Minnesota School of Medicine Targeting AXL as a novel strategy Katherine Fuh, M.D., Ph.D. University of California, San Francisco Immunotherapy of Ovarian Cancer Oliver Dorigo, M.D., Ph.D. Stanford School of Medicine Identification of PKMYT1 as a vulnerability in CCNE1-amplified cancers Daniel Durocher, Ph.D. Lunenfeld-Tanenbaum Research Institute
Photos
